Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024.
The French National Agency for Medicines and Health Products Safety implemented in 2021 a nationwide experimentation for medical cannabis (MC), designed to a...
CBD Probably Reduces Seizures in Refractory Epilepsy, But Raises Risk of Serious Adverse Events
Cannabidiol 20 mg/kg/day and 10 mg/kg/day probably increased the frequency of participants who achieved a ≥50% reduction in monthly seizures (20 mg/kg/day: RR 1.92; 95% CI 1.49–2.46; 10 mg/kg/day: RR 1.94; 95% CI 1.32–2.86, moderate certainty). The…
Association of Multimodal Cannabis Use with Adverse Events among Adolescents and Young Adults.
The ways cannabis is consumed, or modes of use, have increased and diversified in recent years, especially among young people. Associations of multimodal can...
Can CBD Cause Gynaecomastia? Evidence, Hormones, and Safe Use – Bolt Pharmacy
✦ New CED Clinical Relevance #60Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic Endocrine EffectsCbdAdverse EventsMale…
Cannabinoids Show Modest, Low-Certainty Benefits for a Few Mental Health Conditions—But Widespread Clinical Use Is Not Justified
Given the scarcity of evidence, the routine use of cannabinoids for the treatment of mental disorders and SUDs is currently rarely justified.